Relative Value Partners Group LLC Acquires New Stake in Trupanion Inc (TRUP)

Relative Value Partners Group LLC acquired a new position in shares of Trupanion Inc (NASDAQ:TRUP) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 24,243 shares of the financial services provider’s stock, valued at approximately $725,000.

Several other hedge funds have also recently bought and sold shares of the company. Nine Ten Capital Management LLC boosted its position in shares of Trupanion by 55.7% during the first quarter. Nine Ten Capital Management LLC now owns 2,156,419 shares of the financial services provider’s stock worth $64,455,000 after buying an additional 771,552 shares during the period. BlackRock Inc. boosted its position in shares of Trupanion by 1.9% during the first quarter. BlackRock Inc. now owns 1,335,808 shares of the financial services provider’s stock worth $39,927,000 after buying an additional 24,927 shares during the period. Baillie Gifford & Co. boosted its position in shares of Trupanion by 10.0% during the first quarter. Baillie Gifford & Co. now owns 1,171,305 shares of the financial services provider’s stock worth $35,010,000 after buying an additional 106,434 shares during the period. State of New Jersey Common Pension Fund D acquired a new position in shares of Trupanion during the first quarter worth about $11,956,000. Finally, Renaissance Technologies LLC boosted its position in shares of Trupanion by 3.0% during the fourth quarter. Renaissance Technologies LLC now owns 392,900 shares of the financial services provider’s stock worth $11,500,000 after buying an additional 11,616 shares during the period. 87.65% of the stock is owned by institutional investors.

Get Trupanion alerts:

In other news, Director Murray B. Low sold 3,000 shares of the business’s stock in a transaction dated Friday, May 11th. The shares were sold at an average price of $27.97, for a total value of $83,910.00. Following the completion of the sale, the director now owns 192,031 shares in the company, valued at approximately $5,371,107.07. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Darryl Rawlings sold 3,500 shares of the business’s stock in a transaction dated Thursday, March 8th. The shares were sold at an average price of $31.93, for a total transaction of $111,755.00. Following the completion of the sale, the insider now owns 1,375,976 shares of the company’s stock, valued at approximately $43,934,913.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 24,500 shares of company stock valued at $690,365. Company insiders own 20.70% of the company’s stock.

Shares of NASDAQ TRUP opened at $31.65 on Tuesday. Trupanion Inc has a 52 week low of $17.05 and a 52 week high of $37.13. The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 0.31. The company has a market cap of $987.07 million, a P/E ratio of -452.14 and a beta of 0.59.

Trupanion (NASDAQ:TRUP) last posted its quarterly earnings results on Tuesday, May 1st. The financial services provider reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Trupanion had a negative net margin of 0.58% and a negative return on equity of 6.54%. The business had revenue of $69.76 million during the quarter, compared to the consensus estimate of $69.12 million. During the same quarter in the prior year, the firm posted ($0.05) EPS. The company’s revenue for the quarter was up 27.5% compared to the same quarter last year. equities research analysts anticipate that Trupanion Inc will post -0.12 EPS for the current year.

Several research analysts have recently weighed in on TRUP shares. Zacks Investment Research cut Trupanion from a “buy” rating to a “hold” rating in a research report on Thursday, February 15th. Lake Street Capital increased their price target on Trupanion from $32.00 to $41.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. Canaccord Genuity reissued a “buy” rating and set a $40.00 price target on shares of Trupanion in a research report on Wednesday, May 2nd. BidaskClub raised Trupanion from a “sell” rating to a “hold” rating in a research report on Thursday, May 3rd. Finally, Stifel Nicolaus reissued a “buy” rating and set a $34.00 price target (up from $33.00) on shares of Trupanion in a research report on Wednesday, February 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $36.29.

About Trupanion

Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on monthly subscription basis in the United States, Canada, and Puerto Rico. The company operates through Subscription Business and Other Business segments. It serves pet owners and veterinarians through third-party referrals and online member acquisition channels.

Want to see what other hedge funds are holding TRUP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trupanion Inc (NASDAQ:TRUP).

Dunkin’ Brands (DNKN) Expected to Post Quarterly Sales of $342.67 Million

Equities analysts expect that Dunkin’ Brands (NASDAQ:DNKN) will report sales of $342.67 million for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Dunkin’ Brands’ earnings, with the highest sales estimate coming in at $348.90 million and the lowest estimate coming in at $334.91 million. Dunkin’ Brands posted sales of $218.52 million during the same quarter last year, which suggests a positive year over year growth rate of 56.8%. The business is scheduled to announce its next quarterly earnings report on Thursday, July 26th.

On average, analysts expect that Dunkin’ Brands will report full year sales of $1.32 billion for the current fiscal year, with estimates ranging from $1.31 billion to $1.33 billion. For the next financial year, analysts expect that the firm will post sales of $1.37 billion per share, with estimates ranging from $1.36 billion to $1.39 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that follow Dunkin’ Brands.

Get Dunkin' Brands alerts:

Dunkin’ Brands (NASDAQ:DNKN) last posted its quarterly earnings results on Thursday, April 26th. The restaurant operator reported $0.62 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.52 by $0.10. The business had revenue of $301.30 million during the quarter, compared to analysts’ expectations of $303.72 million. Dunkin’ Brands had a net margin of 36.40% and a negative return on equity of 75.12%. The business’s quarterly revenue was up 1.7% on a year-over-year basis. During the same quarter last year, the company posted $0.54 earnings per share.

A number of research firms have issued reports on DNKN. ValuEngine raised shares of Dunkin’ Brands from a “hold” rating to a “buy” rating in a report on Monday, May 7th. BidaskClub raised shares of Dunkin’ Brands from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 9th. BTIG Research reaffirmed a “hold” rating on shares of Dunkin’ Brands in a report on Sunday, April 29th. Piper Jaffray Companies reaffirmed a “neutral” rating and issued a $62.00 price target (up previously from $59.00) on shares of Dunkin’ Brands in a report on Thursday, February 22nd. Finally, Stephens raised their price target on shares of Dunkin’ Brands from $54.00 to $66.00 and gave the stock a “weight” rating in a report on Monday, February 5th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Dunkin’ Brands currently has a consensus rating of “Buy” and a consensus target price of $64.37.

In related news, insider John L. Clare sold 13,388 shares of the firm’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $62.02, for a total transaction of $830,323.76. Following the sale, the insider now owns 29,772 shares in the company, valued at $1,846,459.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Katherine D. Jaspon sold 1,530 shares of the firm’s stock in a transaction on Tuesday, May 8th. The shares were sold at an average price of $64.84, for a total transaction of $99,205.20. The disclosure for this sale can be found here. In the last three months, insiders have sold 280,583 shares of company stock valued at $17,414,472. 3.00% of the stock is currently owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Vaughan Nelson Investment Management L.P. grew its position in Dunkin’ Brands by 9.4% during the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 887,675 shares of the restaurant operator’s stock valued at $57,229,000 after buying an additional 75,975 shares during the period. American International Group Inc. grew its position in Dunkin’ Brands by 1.2% during the fourth quarter. American International Group Inc. now owns 198,566 shares of the restaurant operator’s stock valued at $12,802,000 after buying an additional 2,405 shares during the period. Landscape Capital Management L.L.C. acquired a new stake in Dunkin’ Brands during the fourth quarter valued at $13,251,000. Deutsche Bank AG grew its position in Dunkin’ Brands by 6.7% during the fourth quarter. Deutsche Bank AG now owns 530,470 shares of the restaurant operator’s stock valued at $34,196,000 after buying an additional 33,383 shares during the period. Finally, Fred Alger Management Inc. grew its position in shares of Dunkin’ Brands by 5.1% in the fourth quarter. Fred Alger Management Inc. now owns 61,043 shares of the restaurant operator’s stock valued at $3,935,000 after purchasing an additional 2,967 shares during the period. Institutional investors own 98.94% of the company’s stock.

Shares of NASDAQ DNKN traded down $0.90 during midday trading on Friday, reaching $65.16. The company had a trading volume of 1,088,489 shares, compared to its average volume of 1,137,161. The stock has a market cap of $5.48 billion, a P/E ratio of 26.81, a P/E/G ratio of 1.92 and a beta of 0.30. Dunkin’ Brands has a 1 year low of $50.89 and a 1 year high of $68.45. The company has a current ratio of 1.50, a quick ratio of 1.50 and a debt-to-equity ratio of -3.54.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 6th. Investors of record on Tuesday, May 29th will be issued a dividend of $0.3475 per share. The ex-dividend date is Friday, May 25th. This represents a $1.39 annualized dividend and a dividend yield of 2.13%. Dunkin’ Brands’s dividend payout ratio (DPR) is presently 57.20%.

About Dunkin’ Brands

Dunkin' Brands Group, Inc, together with its subsidiaries, develops, franchises, and licenses quick service restaurants worldwide. The company operates through four segments: Dunkin' Donuts U.S., Dunkin' Donuts International, Baskin-Robbins International, and Baskin-Robbins U.S. Its restaurants offer hot and cold coffee, baked goods, donuts, bagels, muffins, breakfast sandwiches, hard and soft serve ice creams, frozen yogurts, shakes, malts, floats, and cakes.

Innovative Industrial Properties: Betting On Medical Cannabis

Innovative Industrial Properties (IIPR) is breaking out higher following continued expansion in the company's operations. As the medical cannabis industry grows in the U.S., IIPR is at the forefront of providing cultivation and processing facilities to such companies. As regulation is rolled back on medical cannabis, its share price has trended higher, currently trading near record levels. I am buying stock in this name as it presents a first mover advantage in the burgeoning industry.

Fundamental Narrative

IIPR is an attractive buy at current levels due to the expanding scope of the legalized medical cannabis industry in the U.S., as well as the company being at the forefront of the REIT industry in this category.

The company is a self-advised Maryland corporation focused on the acquisition, ownership and management of specialized industrial properties leased to experienced, state-licensed operators for their regulated medical-use cannabis facilities.

At the end of the most recent quarter, IIPR owned five properties in four states, totaling approximately 617,000 square feet, which were 100% leased on a long-term basis to high quality licensed, medical-use cannabis operators, according to its earnings call. Its initial blended yield on these properties is 15.8% with each lease providing minimum annual escalations ranging from 3.25% to 4%.

The company is very active in terms of acquisitions as they continuously look for opportunities in this growing industry. In December, they closed on a sale-leaseback transaction for a 358,000 square-foot medical-use cannabis cultivation and processing facility with a farm in Arizona and closed on two other sale-leaseback transactions with Vireo in the state of New York, as well as Minnesota in October and November, according to its earnings call.

The medical-use cannabis industry is constantly evolving, including strong growth of existing state markets and the rollout of new programs passed to numerous states by popular vote or legislation in recent years.

Within the nascent industry, management is witnessing amazing growth with state regulated medical-use cannabis markets now comprising a large majority of the United States. Congress has enacted spending bills since 2014 with a provision that has been interpreted by courts as preventing the Department of Justice from using funds to interfere with the implementation of state medical-use cannabis laws, aiding IIPR's ultimate growth effort.

The provision was again included in the congressional spending bill enacted on March 23rd, which carry through September 30 of 2018, according to management. This signals that the Federal Government is largely stepping out of the way of the industry as many of the medical cannabis studies have shown to address the needs of a number of important ailments.

The company's current markets are in New York, Arizona, Maryland, and Minnesota, where they have five properties located, with continued potential in each. IIPR is seeing a lot of encouraging signs with both growth and regulation rollback in New York.

The company purchased its first New York property in December 2016 with PharmaCann for a 15-year initial term and are all in initial yield of about 17% on a triple net basis, according to its earnings call. PharmaCann is a multistate operator with two cultivation facilities and four medical-use cannabis dispensers in Illinois, as well as IIPR's cultivation facility in four medical-use cannabis dispensaries in New York.

In order to enable broader access to treatment, New York has taken several positive steps including expansion of the pool of potential recommending health professionals to include nurse practitioners and physician assistants, allowing for home delivery of the medicine, the streamlining of the registration process for practitioners and certification process for patients and perhaps most importantly the introduction of chronic pain and PTSD as additional qualifying condition, according to its earnings call.

The market potential and estimated overall size of the illicit market in New York is nearly $3 billion, with an estimated $254 million of sales in New York's legal market by 2021, representing a compounded annual growth rate from 2016 of 48%, signaling the large growth potential for IIPR and its partners.

Its partner in Arizona, Pharma, is one of the largest wholesalers of medical-use cannabis in the Arizona market, with a highly experienced multidisciplinary management team that is well positioned to grow the Pharma's market share in Arizona and facilitate expansion into other states, according to its earnings call. Arizona's medical-use cannabis program is further along and mature than New York, having commenced medical-use cannabis sales in 2010.

According to the Arizona Department of Health Services, there are over 150,000 qualifying patients in the Arizona's medical cannabis program as of February 2018, representing an increase of over 30% year-over-year with over 85% of registered patients utilizing medical cannabis to treat chronic pain, according to its earnings call.

Moreover, in Maryland, although it's still in its very early stages with the first dispensary opened in late 2017, management is optimistic regarding the development of the legal medical-use cannabis market, driven by Maryland's population size and anticipated demand, the inclusion of PTSD in chronic pain among the initial qualifying conditions and the general view from regulators and policymakers that the industry represents an economic development opportunity, according to management.

Within its acquisition pipeline, IIPR is focused on investing the proceeds from its recently completed follow-on common stock offering in high quality assets and top tiered tenants. In the first quarter, management executed agreements to purchase two properties for a total investment of $10.5 million.

In addition, they executed two nonbinding letters of intent for two properties representing a total expected additional investment of approximately $25 million to $30 million with final amounts determined after they complete its review, signaling the growth prospects for the company. Management is actively evaluating its pipeline of approximately $100 million in additional acquisitions spanning numerous states that have approved medical-use cannabis programs.

With regards to California, management is engaged in numerous discussions with high-quality cultivators there. As with any emerging dynamic high growth industry, IIPR is developing its acquisition strategy and criteria accordingly.

Below is a chart of the company's revenue and earnings per share. Over the last few months, IIPR's revenue has risen substantially, while its EPS is in positive territory. With management's continued focus of expansion alongside more states legalizing medical cannabis, the company's operations look primed to continue growing both on the top and bottom line.

Price Action

The company's share price has traded higher since its IPO, with recent strength on its strong earnings announcement. Advancements in the medical cannabis industry, as well as deregulation in many states have aided the company's share price in recent months. The company is actively looking to expand into new properties as opportunities arise.

Its share price is breaking out to record highs, following a recent consolidation over the last few months. Breaking above the $34 level is significant as it had acted as strong resistance in recent months. The continued expansion of this industry should fuel the company's share price higher in coming quarters.

Conclusion

IIPR is breaking out higher following continued expansion in the company's operations. As the medical cannabis industry grows in the U.S., IIPR is at the forefront of providing cultivation and processing facilities to such companies. As regulation is rolled back on medical cannabis, its share price has trended higher, currently trading near record levels. I am buying stock in this name as it presents a first mover advantage in the burgeoning industry.

Disclosure: I am/we are long IIPR.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

U.K. stocks rebound from 2-day losing run as Brexit jitters drive pound lower

U.K. stocks advanced on Friday, set to break a two-day losing streak, as the pound selloff resumed on signs Brexit discussions between Brussels and London are close to a painful breakdown.

Traders reacted little to data confirming the U.K. economy expanded at its slowest pace in five years in the first quarter.

What are markets doing?

The FTSE 100 index UKX, +0.27% �gained 0.3% to 7,739.78, trimming its weekly loss to 0.4%. The London benchmark has moved sharply lower over the last two days on increasing concerns about trade talks between the U.S. and China, and on worries over President Donald Trump��s decision to pull out of a historic summit with North Korea.

The pound GBPUSD, -0.1794% �fell to $1.3355, from $1.3379 late Thursday in New York. Sterling touched a fresh 2018 low earlier this week wound $1.3305.

What is driving the market?

The fall in sterling provided a lift to the FTSE 100 on Friday. A weaker pound tends to boost the FTSE 100, as the index��s components conduct the bulk of their business overseas and a softening in sterling lifts revenue when converted back into the U.K. currency.

Sterling was hit by concerns over the Brexit negotiations after European Union officials said the British government was ��chasing a fantasy�� in the talks, according to the Guardian newspaper. The comment came after a tense week of discussions, with the two sides fighting over the future security relationship. Fears are the lack of agreement could lead to a complete breakdown in negotiations.

Headline of the day... pic.twitter.com/7mpPA9xAv1

— Ryan Sabey (@ryansabey) May 25, 2018

Bank of England Governor Mark Carney warned in a speech late Thursday that a ��disorderly�� Brexit could trigger another interest rate cut to support the British economy.

Carney will speak again on Friday at the Swedish Riksbank Anniversary Conference in Stockholm at 2:20 p.m. London time, or 9:20 a.m. Eastern Time.

Meanwhile, calm appeared to be returning to the market after a week of geopolitical ups and downs, as North Korea made a restrained response to Trump��s withdrawal from a planned June meeting with Kim Jong Un. A senior foreign ministry official said North Korea was still willing to meet and ��sit down face-to-face with the U.S. and resolve issues anytime and in any format.��

The session may see thin volumes as traders head out for a long weekend, as the market will close Monday for the late May bank holiday.

What data are in focus?

The U.K. economy expanded at 0.1% in the first-quarter, confirming a previous estimate from the Office for National Statistics. The reading was in line with expectations.

The slow growth rate marks period since the fourth quarter of 2012 and has largely been attributed to exceptionally cold weather in February and March.

When the first GDP reading came out in late April, it shocked investors with how weak it was. At the time, it sent the pound sharply lower, as it was seen as completely ruling out a BOE rate hike in May.

At the May BOE meeting, the central bank kept rates on hold, with Carney citing temporary weakness in the economy as the reason to stay put.

What are strategists saying?

��If Bank of England Governor Mark Carney was hoping for a surprise uplift in the latest GDP estimate this morning, he was dealt yet another blow,�� said Anthony Kurukgy, senior sales trader at Foenix Partners, in a note.

��The latest reading, which came in line with market expectations (0.1%) reaffirms the U.K. central bank��s views that a combination of stagnated growth and ��softer�� data will only keep the likelihood of U.K. interest rate hikes on hold. With the ��unreliable boyfriend�� at the helm, there��s an argument to say that one interest rate rise in 2018 isn��t exactly a forgone conclusion,�� he added.

Stock movers

Shares of GVC Holdings PLC GVC, +2.95% �rose 1.9% after the sports-betting and gaming group said revenue increased in the 20-week period ending May 20 even as U.K. sales were hit by adverse weather.

AstraZeneca PLC AZN, +0.64% AZN, +0.11% �added 1% after the drug giant reported positive results for its Imfinzi cancer drug.

Royal Mail PLC RMG, -3.37% �dropped 2.9% after Berenberg cut the delivery company to sell from hold, according to Dow Jones Newswires. Berenberg said Royal Mail faces little profit growth in coming years, as its customers are likely to scale back on sending out marketing materials due to the EU��s new General Data Protection Regulation. The GDPR privacy rules come into effect on Friday.

Read: 5 things to know about the GDPR rules taking effect Friday �� which could cost big, bad tech billions

Sara Sjolin

Sara Sjolin is a MarketWatch reporter based in London. Follow her on Twitter @sarasjolin.

We Want to Hear from You

Join the conversation

Comment Related Topics United Kingdom London Stock Exchange London Markets Bank of England Europe European Markets Quote References UKX +20.79 +0.27% GBPUSD -0.0024 -0.1794% GVC +29.00 +2.95% AZN +35.00 +0.64%

ETRADE Capital Management LLC Invests $220,000 in CNH Industrial (CNHI) Stock

ETRADE Capital Management LLC bought a new position in shares of CNH Industrial (NYSE:CNHI) in the 1st quarter, Holdings Channel reports. The fund bought 17,752 shares of the company’s stock, valued at approximately $220,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Franklin Resources Inc. grew its stake in CNH Industrial by 93.2% during the 4th quarter. Franklin Resources Inc. now owns 35,031,154 shares of the company’s stock worth $469,479,000 after purchasing an additional 16,900,395 shares in the last quarter. AXA boosted its position in shares of CNH Industrial by 4.9% during the 4th quarter. AXA now owns 16,568,118 shares of the company’s stock worth $222,013,000 after acquiring an additional 766,516 shares in the last quarter. Gamco Investors INC. ET AL boosted its position in shares of CNH Industrial by 5.9% during the 4th quarter. Gamco Investors INC. ET AL now owns 10,694,912 shares of the company’s stock worth $143,312,000 after acquiring an additional 596,525 shares in the last quarter. Amundi Pioneer Asset Management Inc. acquired a new position in shares of CNH Industrial during the 4th quarter worth about $135,437,000. Finally, TIAA CREF Investment Management LLC boosted its position in shares of CNH Industrial by 53.6% during the 4th quarter. TIAA CREF Investment Management LLC now owns 9,196,954 shares of the company’s stock worth $123,239,000 after acquiring an additional 3,210,306 shares in the last quarter. 19.29% of the stock is owned by hedge funds and other institutional investors.

Get CNH Industrial alerts:

CNH Industrial opened at $12.62 on Thursday, Marketbeat Ratings reports. CNH Industrial has a fifty-two week low of $10.78 and a fifty-two week high of $15.65. The company has a quick ratio of 3.88, a current ratio of 5.05 and a debt-to-equity ratio of 6.02. The stock has a market capitalization of $17.47 billion, a PE ratio of 26.29 and a beta of 1.02.

CNH Industrial (NYSE:CNHI) last posted its earnings results on Friday, April 27th. The company reported $0.14 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.08 by $0.06. CNH Industrial had a return on equity of 18.25% and a net margin of 1.56%. The business had revenue of $6.77 billion during the quarter, compared to the consensus estimate of $6.40 billion. During the same period in the previous year, the business earned $0.04 EPS. The business’s quarterly revenue was up 17.1% on a year-over-year basis. equities research analysts expect that CNH Industrial will post 0.7 EPS for the current year.

CNH Industrial announced that its board has authorized a stock buyback plan on Tuesday, January 30th that permits the company to repurchase $700.00 million in shares. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company’s board believes its shares are undervalued.

CNHI has been the subject of several analyst reports. Bank of America upped their price objective on CNH Industrial from $17.00 to $18.00 and gave the stock a “buy” rating in a research report on Thursday, February 1st. Zacks Investment Research cut CNH Industrial from a “hold” rating to a “sell” rating in a research report on Monday, February 12th. TheStreet cut CNH Industrial from a “c” rating to a “d+” rating in a research report on Monday, February 12th. Stifel Nicolaus reaffirmed a “hold” rating and set a $14.00 price objective (up from $13.40) on shares of CNH Industrial in a research report on Tuesday, February 20th. Finally, Morgan Stanley initiated coverage on CNH Industrial in a research report on Friday, March 2nd. They set an “equal weight” rating and a $15.00 price objective for the company. Seven investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $14.95.

CNH Industrial Profile

CNH Industrial N.V. designs, produces, markets, sells, and finances agricultural and construction equipment, trucks, commercial vehicles, and buses worldwide. The company operates in five segments: Agricultural Equipment, Construction Equipment, Commercial Vehicles, Powertrain, and Financial Services.

Want to see what other hedge funds are holding CNHI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CNH Industrial (NYSE:CNHI).

Buy Berger Paints, target Rs 325: Ashish Chaturmohta

Ashish Chaturmohta

Berger Paints�has been consolidating at higher levels between Rs 285 and Rs 230 odd levels for the past one year. For the past couple of weeks, the stock has witnessed above average volumes and positive price movement indicating buying participation in the stock.

In the last one-month, the stock has formed higher lows indicating buying coming in at higher levels. Currently, the stock is trading around at its all-time high levels and generally post the breakout price continue to rally.

The relative strength index or the RSI has turned up after taking after support from its average. The Daily MACD has given a positive crossover with its average above the neutral level of zero suggesting the stock is likely to see a breakout on the upside.

Thus, traders can buy the stock at current level and on dips towards Rs 280 with a stop loss below Rs 272, and a target of Rs 325 levels.

Disclaimer: The author is Head Technical and Derivatives, Sanctum Wealth Management. The views and investment tips expressed by investment expert on Moneycontrol.com are his own and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Top 10 Penny Stocks To Invest In Right Now

tags:SORL,RMCF,SAFM,TIS,CNR,BDL,TSN,BDSI,SMSI,NRG,

With lists of more than 200 marijuana stocks to invest in floating around the Internet, finding the right marijuana penny stock to watch is difficult. But finding the right stock can double your money, just like when Canopy Growth Corp. (OTCMKTS: TWMJF) surged 140.09% over the last year.

We've done the hard work of combing through all available marijuana penny stocks to find one worth your attention, and we'll reveal it in just a bit.

Now, it's true most pot stocks are penny stocks, which are notorious for wild price swings. The volatility causes a lot of investors to buy high and sell low, which will always lose your hard-earned money.

Top 10 Penny Stocks To Invest In Right Now: SORL Auto Parts Inc.(SORL)

Advisors' Opinion:

• [By Lisa Levin] Gainers Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares rose 14.1 percent to $3.65 in the pre-market trading session after reporting 2017 year-end results. LightPath Technologies, Inc. (NASDAQ: LPTH) rose 13.3 percent to $2.43 in pre-market trading after reporting a third-quarter earnings beat. MYnd Analytics, Inc. (NASDAQ: MYND) rose 10.5 percent to $3.49 in pre-market trading. MYnd Analytics reported a Q2 net loss of $2.7 million on revenue of $459,900. SORL Auto Parts, Inc. (NASDAQ: SORL) shares rose 8.4 percent to $5.68 in pre-market trading after reporting upbeat Q1 results. Famous Dave's of America, Inc. (NASDAQ: DAVE) shares rose 7.7 percent to $8.40 in pre-market trading after the company reported upbeat earnings for its first quarter on Monday. Xenon Pharmaceuticals Inc. (NASDAQ: XENE) rose 7.5 percent to $6.45 in pre-market trading after the company presented XEN901 Phase 1 clinical update and XEN1101 TMS pharmacodynamic Phase 1 data. Mimecast Ltd (NASDAQ: MIME) rose 6.5 percent to $43.50 in pre-market trading following a first-quarter sales beat. Boxlight Corporation (NASDAQ: BOXL) rose 6 percent to $12.50 in pre-market trading after surging 77.44 percent on Monday. Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares rose 6 percent to $26.05 in pre-market trading after climbing 3.58 percent on Monday. PPDAI Group Inc. (NASDAQ: PPDF) rose 4.7 percent to $7.20 in pre-market trading following Q1 results. Xunlei Limited (NASDAQ: XNET) rose 4.1 percent to $13.88 in pre-market trading after gaining 2.54 percent on Monday. Valeant Pharmaceuticals International, Inc. (NYSE: VRX) shares rose 4.5 percent to $21.73 in pre-market trading. Mizuho upgraded Valeant from Neutral to Buy. Bovie Medical Corporation (NYSE: BVX) rose 4.1 percent to $3.80 in pre-market trading after reporting a first-quarter sales beat. Myomo, Inc. (NYSE: MYO) rose 3.4 percent to $4.00 in pre-market trading after jumping 23.25 percent o
• [By Lisa Levin]

  Shares of SORL Auto Parts, Inc. (NASDAQ: SORL) got a boost, shooting up 13 percent to $5.90 after reporting upbeat Q1 results.

  Hollysys Automation Technologies Ltd. (NASDAQ: HOLI) shares were also up, gaining 24 percent to $27.3947 following Q3 results.

• [By Lisa Levin]

  SORL Auto Parts, Inc. (NASDAQ: SORL) is expected to report quarterly earnings at $0.19 per share on revenue of $86.96 million.

  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) is projected to report quarterly loss at $0.39 per share.

• [By Lisa Levin] Gainers Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares climbed 70.3 percent to $5.45 after reporting 2017 year-end results. MEDIGUS Ltd/S ADR (NASDAQ: MDGS) surged 39.8 percent to $1.58 in reaction to its Monday announcement of a distribution agreement. The medical device company said it reached an agreement to distribute its minimally invasive medical devices in Turkey, Azerbaijan and Georgia. Arcadia Biosciences, Inc. (NASDAQ: RKDA) gained 25.6 percent to $11.50. Arcadia Biosciences reported that Albert D. Bolles, Ph.D. has joined its board of directors. Aytu Bioscience Inc (NASDAQ: AYTU) shares jumped 21.8 percent to $0.4798 after the company late Monday reported lighter-than-expected Q1 loss. Hollysys Automation Technologies Ltd. (NASDAQ: HOLI) shares gained 21.1 percent to $26.77 following Q3 results. Pfenex Inc. (NYSE: PFNX) rose 16.8 percent to $7.1271 after the company announced the positive top-line PF708 study results in Osteoporosis patients that showed no imbalances in severity or incidence of adverse events. MEI Pharma, Inc. (NASDAQ: MEIP) rose 13.8 percent to $2.88. Red Violet, Inc. (NASDAQ: RDVT) jumped 13.1 percent to $6.41 after reporting Q1 results. SORL Auto Parts, Inc. (NASDAQ: SORL) shares gained 12 percent to $5.87 after reporting upbeat Q1 results. Bovie Medical Corporation (NYSE: BVX) gained 8.4 percent to $3.96 after reporting a first-quarter sales beat. Rosehill Resources Inc. (NASDAQ: ROSE) surged 8.4 percent to $7.90 after announcing Q1 results. LiqTech International, Inc. (NASDAQ: LIQT) rose 8.1 percent to $0.5171 following Q1 results. ProPhase Labs, Inc. (NASDAQ: PRPH) rose 7.7 percent to $5.6103 following Q1 results. Nine Energy Service, Inc. (NYSE: NINE) shares climbed 7.4 percent to $35.90. Xenon Pharmaceuticals Inc. (NASDAQ: XENE) rose 6.7 percent to $6.40 after the company presented XEN901 Phase 1 clinical update and XEN1101 TMS pharmacodynamic Phase 1 data. MYnd
• [By Lisa Levin] Gainers Red Violet, Inc. (NASDAQ: RDVT) rose 75.31 percent to close at $9.94 after reporting Q1 results. Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares jumped 40.62 percent to close at $4.50 on Tuesday after reporting 2017 year-end results. MEI Pharma, Inc. (NASDAQ: MEIP) gained 34.39 percent to close at $3.40. MEDIGUS Ltd/S ADR (NASDAQ: MDGS) gained 32.74 percent to close at $1.50 in reaction to its Monday announcement of a distribution agreement. The medical device company said it reached an agreement to distribute its minimally invasive medical devices in Turkey, Azerbaijan and Georgia. Pfenex Inc. (NYSE: PFNX) surged 31.15 percent to close at $8.00 after the company announced the positive top-line PF708 study results in Osteoporosis patients that showed no imbalances in severity or incidence of adverse events. Arcadia Biosciences, Inc. (NASDAQ: RKDA) rose 21.07 percent to close at $11.09. Arcadia Biosciences reported that Albert D. Bolles, Ph.D. has joined its board of directors. Genprex, Inc. (NASDAQ: GNPX) rose 20.23 percent to close at $10.58. Turtle Beach Corporation (NASDAQ: HEAR) shares gained 17.62 percent to close at $17.82. Aptevo Therapeutics Inc. (NASDAQ: APVO) rose 17.1 percent to close at $5.82. Phoenix New Media Limited (NYSE: FENG) shares jumped 16.23 percent to close at $4.87 following Q1 earnings. Stein Mart, Inc. (NASDAQ: SMRT) rose 16.04 percent to close at $3.69. PPDAI Group Inc. (NASDAQ: PPDF) climbed 15.99 percent to close at $7.98 following Q1 results. Tyme Technologies, Inc. (NASDAQ: TYME) rose 15.93 percent to close at $3.42. LiqTech International, Inc. (NASDAQ: LIQT) gained 15.59 percent to close at $0.5532 following Q1 results. Sophiris Bio, Inc. (NASDAQ: SPHS) gained 13.92 percent to close at $3.52 on Tuesday following Q1 results. Euroseas Ltd. (NASDAQ: ESEA) jumped 13.4 percent to close at $2.37. Iteris, Inc. (NASDAQ: ITI) shares surged 13.05 percent to close

Top 10 Penny Stocks To Invest In Right Now: Rocky Mountain Chocolate Factory Inc.(RMCF)

Advisors' Opinion:

• [By Max Byerly]

  Rocky Mountain Chocolate Factory (NASDAQ: RMCF) and Tootsie Roll Industries (NYSE:TR) are both small-cap retail/wholesale companies, but which is the better investment? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

• [By Ethan Ryder]

  Rocky Mountain Chocolate Factory (NASDAQ: RMCF) and Tootsie Roll Industries (NYSE:TR) are both small-cap retail/wholesale companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, dividends and analyst recommendations.

Top 10 Penny Stocks To Invest In Right Now: Sanderson Farms Inc.(SAFM)

Advisors' Opinion:

• [By Logan Wallace]

  ValuEngine cut shares of Sanderson Farms (NASDAQ:SAFM) from a strong-buy rating to a buy rating in a research report released on Wednesday morning.

Top 10 Penny Stocks To Invest In Right Now: Orchids Paper Products Company(TIS)

Advisors' Opinion:

• [By Lisa Levin] Gainers Check-Cap Ltd. (NASDAQ: CHEK) shares jumped 104.82 percent to close at $14.87 on Tuesday. EVINE Live Inc. (NASDAQ: EVLV) rose 31.25 percent to close at $1.06. The pay-TV home shopping company was named as a potential acquisition target by TechCrunch. According to the publication, Amazon.com, Inc. (NASDAQ: AMZN) is exploring ways of marketing its products and services to consumers beyond the internet. SemiLEDs Corporation (NASDAQ: LEDS) shares climbed 27.16 percent to close at $4.26 on Tuesday. Atossa Genetics Inc. (NASDAQ: ATOS) gained 27.09 percent to close at $3.80. Atossa Genetics disclosed that it has Received positive interim review from the Independent Safety Committee in Phase 1 Topical endoxifen dose escalation study in men. Heidrick & Struggles International, Inc. (NASDAQ: HSII) surged 17.13 percent to close at $37.95 as the company posted upbeat results for its first quarter. Santander Consumer USA Holdings Inc. (NYSE: SC) shares gained 15.91 percent to close at $18.21 following upbeat quarterly earnings. Riot Blockchain, Inc. (NASDAQ: RIOT) shares jumped 15.73 percent to close at $7.58 on Tuesday after declining 1.50 percent on Monday. Sanmina Corp (NASDAQ: SANM) shares gained 14.62 percent to close at $31.75 as the company reported stronger-than-expected earnings for its second quarter on Monday. Orchids Paper Products Company (NYSE: TIS) jumped 12.86 percent to close at $7.37. Orchids Paper Products is expected to report its Q1 financial results on Wednesday, April 25, 2018. Helix Energy Solutions Group, Inc. (NYSE: HLX) rose 12.8 percent to close at $7.05 following strong quarterly results. Avid Bioservices, Inc. (NASDAQ: CDMO) rose 12.72 percent to close at $3.81. Genprex, Inc. (NASDAQ: GNPX) gained 12.61 percent to close at $5.00. Obalon Therapeutics, Inc. (NASDAQ: OBLN) rose 12.39 percent to close at $3.72. NextDecade Corporation (NASDAQ: NEXT) shares climbed 11.88 percent to close at $7
• [By Lisa Levin] Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares rose 35.8 percent to $4.55. EVINE Live Inc. (NASDAQ: EVLV) gained 28.8 percent to $1.04. The pay-TV home shopping company was named as a potential acquisition target by TechCrunch. According to the publication, Amazon.com, Inc. (NASDAQ: AMZN) is exploring ways of marketing its products and services to consumers beyond the internet. Sanmina Corp (NASDAQ: SANM) shares surged 19.1 percent to $33.00 as the company reported stronger-than-expected earnings for its second quarter on Monday. Heidrick & Struggles International, Inc. (NASDAQ: HSII) gained 14.9 percent to $37.22 as the company posted upbeat results for its first quarter. Santander Consumer USA Holdings Inc. (NYSE: SC) shares climbed 14 percent to $17.90 following upbeat quarterly earnings. Helix Energy Solutions Group, Inc. (NYSE: HLX) climbed 14 percent to $7.12 following strong quarterly results. Check-Cap Ltd. (NASDAQ: CHEK) gained 13.6 percent to $8.25. Atossa Genetics Inc. (NASDAQ: ATOS) rose 11.8 percent to $3.34. Atossa Genetics disclosed that it has Received positive interim review from the Independent Safety Committee in Phase 1 Topical endoxifen dose escalation study in men. Cadence Design Systems, Inc. (NASDAQ: CDNS) gained 11.6 percent to $40.99 after the company posted upbeat Q1 results and issued a strong Q2 forecast. Genprex, Inc. (NASDAQ: GNPX) climbed 11.2 percent to $4.9363. Mitel Networks Corporation (NASDAQ: MITL) rose 10.5 percent to $11.23 after the company agreed to be acquired by affiliates of Searchlight Capital Partners for $2.0 billion. Systemax Inc. (NYSE: SYX) rose 10.2 percent to $30.86. Sidoti & Co. upgraded Systemax from Neutral to Buy. Orchids Paper Products Company (NYSE: TIS) surged 9.2 percent to $7.13. Orchids Paper Products is expected to report its Q1 financial results on Wednesday, April 25, 2018. New Oriental Education & Technology Group Inc. (NYSE: EDU) rose

Top 10 Penny Stocks To Invest In Right Now: China Metro-Rural Holdings Limited(CNR)

Advisors' Opinion:

• [By Shane Hupp]

  Wall Street analysts expect that Canadian National Railway (NYSE:CNI) (TSE:CNR) will announce $1.02 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Canadian National Railway’s earnings, with the highest EPS estimate coming in at $1.06 and the lowest estimate coming in at $0.97. Canadian National Railway reported earnings per share of $1.00 in the same quarter last year, which would suggest a positive year over year growth rate of 2%. The company is expected to announce its next quarterly earnings results on Tuesday, July 24th.

• [By Max Byerly]

  Canadian National Railway (NYSE:CNI) (TSE:CNR) – Cormark raised their Q3 2018 earnings per share (EPS) estimates for Canadian National Railway in a research report issued to clients and investors on Tuesday, April 10th. Cormark analyst D. Tyerman now expects that the transportation company will post earnings per share of $1.15 for the quarter, up from their previous estimate of $1.14.

Top 10 Penny Stocks To Invest In Right Now: Flanigan's Enterprises Inc.(BDL)

Advisors' Opinion:

• [By Lisa Levin] Gainers Blink Charging Co. (NASDAQ: BLNK) shares jumped 26.5 percent to $6.9042. Blink Charging reported Q1 net income of $2.2 million, versus a year-ago net loss of $3.1 million. Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) shares climbed 17.4 percent to $3.11. Eleven Biotherapeutics posted a Q1 loss of $0.11 per share. Flanigan's Enterprises, Inc. (NYSE: BDL) shares jumped 17 percent to $27.97 following Q2 results. Flanigan's Enterprises posted Q2 earnings of $0.75 per share on sales of $29.456 million. Borqs Technologies, Inc. (NASDAQ: BRQS) rose 15.8 percent to $8.05 after reporting Q1 results. Abaxis, Inc. (NASDAQ: ABAX) jumped 15.3 percent to $82.75. Zoetis Inc. (NYSE: ZTS) announced plans to acquire Abaxis for $83 per share in cash. 21Vianet Group, Inc. (NASDAQ: VNET) gained 15.1 percent to $6.33. Gemphire Therapeutics Inc. (NASDAQ: GEMP) rose 13.8 percent to $6.27. Enphase Energy, Inc. (NASDAQ: ENPH) gained 12.8 percent to $5.98. H.C. Wainwright initiated coverage on Enphase Energy with a Buy rating. PetIQ Inc (NASDAQ: PETQ) shares surged 12.1 percent to $21.68 after reporting a first-quarter sales beat. NF Energy Saving Corporation (NASDAQ: NFEC) climbed 11.6 percent to $2.399. Allied Healthcare Products, Inc. (NASDAQ: AHPI) surged 11.4 percent to $3.0643. Boot Barn Holdings, Inc. (NYSE: BOOT) gained 11.1 percent to $24.40 after the company reported upbeat results for its fourth quarter and issued strong first-quarter earnings guidance. Ascena Retail Group, Inc. (NASDAQ: ASNA) rose 10.9 percent to $3.16. Sea Limited (NYSE: SE) gained 10.1 percent to $11.71 after reporting Q1 results. GEE Group, Inc. (NYSE: JOB) climbed 7.9 percent to $2.61 following Q2 results. The ONE Group Hospitality, Inc. (NASDAQ: STKS) gained 7.6 percent to $2.41 after reporting Q1 results. Biolinerx Ltd/S ADR (NASDAQ: BLRX) rose 7.3 percent to $0.8798 after the company was granted a patent approval. The clinical-st

Top 10 Penny Stocks To Invest In Right Now: Tyson Foods Inc.(TSN)

Advisors' Opinion:

• [By ]

  But what investors are overlooking are the fundamental risks to this logic. Corporate earnings are the lifeblood of the market, keep in mind. Higher oil prices have already translated into higher gas prices, which is a key risk to automakers such as Ford (F) and General Motors (GM) that have pivoted big-time to producing SUVs and trucks. Higher oil prices have already taken a toll on earnings for packaged food giants like Proctor & Gamble (PG) and Tyson Foods (TSN) . Now, each are staring at consumer price increases because it costs more to deliver their products to stores.

• [By Lisa Levin] Companies Reporting Before The Bell Tyson Foods, Inc. (NYSE: TSN) is projected to report quarterly earnings at $1.32 per share on revenue of $9.89 billion. Sysco Corporation (NYSE: SYY) is estimated to report quarterly earnings at $0.64 per share on revenue of $14.34 billion. Louisiana-Pacific Corporation (NYSE: LPX) is expected to report quarterly earnings at $0.67 per share on revenue of $692.63 million. Cognizant Technology Solutions Corporation (NASDAQ: CTSH) is estimated to report quarterly earnings at $1.06 per share on revenue of 3.90 billion. Manchester United plc (NYSE: MANU) is estimated to report quarterly loss at $1.35 per share on revenue of $193.67 million. Sempra Energy (NYSE: SRE) is expected to report quarterly earnings at $1.66 per share on revenue of $3.24 billion. Willis Towers Watson Public Limited Company (NYSE: WLTW) is projected to report quarterly earnings at $3.01 per share on revenue of $2.23 billion. Green Plains Inc. (NASDAQ: GPRE) is estimated to report quarterly loss at $0.28 per share on revenue of $922.42 million. TravelCenters of America LLC (NASDAQ: TA) is projected to report quarterly loss at $0.16 per share on revenue of $1.59 billion. Gannett Co., Inc. (NYSE: GCI) is expected to report quarterly earnings at $0.03 per share on revenue of $723.93 million. Welbilt, Inc. (NYSE: WBT) is estimated to report quarterly earnings at $0.11 per share on revenue of $329.71 million. Horizon Pharma Public Limited Company (NASDAQ: HZNP) is projected to report quarterly earnings at $0.07 per share on revenue of $234.17 million.

   

• [By Lisa Levin]

  Some of the stocks that may grab investor focus today are:

  Wall Street expects Sysco Corporation (NYSE: SYY) to report quarterly earnings at $0.64 per share on revenue of $14.34 billion before the opening bell. Sysco shares rose 0.18 percent to close at $62.29 on Friday. Analysts expect Tyson Foods, Inc. (NYSE: TSN) to report quarterly earnings at $1.32 per share on revenue of $9.89 billion before the opening bell. Tyson shares rose 1.39 percent to close at $66.97 on Friday. International Flavors & Fragrances Inc. (NYSE: IFF) reported upbeat earnings for its first quarter and agreed to acquire Frutarom for $7.1 billion. International Flavors shares dropped 5.03 percent to $135.00 in pre-market trading. Before the opening bell, Louisiana-Pacific Corporation (NYSE: LPX) is projected to report quarterly earnings at $0.67 per share on revenue of $692.63 million. Louisiana-Pacific shares gained 2.09 percent to close at $28.32 on Friday. Analysts are expecting Willis Towers Watson Public Limited Company (NYSE: WLTW) to have earned $3.01 per share on revenue of $2.23 billion in the latest quarter. Willis Towers Watson will release earnings before the markets open. Willis Towers Watson shares gained 0.98 percent to close at $148.91 on Friday.

  Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

• [By ]

  Tyson Foods (TSN) CEO Tom Hayes wasn't kidding when he told TheStreet he wanted to make another big acquisition soon. 

  But the argument could be made that Wall Street wasn't expecting his latest food purchase. On Tuesday, Tyson Foods said it will spend $850 million to buy the poultry rendering and blending assets of American Proteins, Inc. and AMPRO Products, Inc.

• [By ]

  Pilgrim's Pride (PPC) : "There are so many things wrong with this one. I'd go with Tyson Foods (TSN) ."

  JB Hunt Transport Services (JBHT) : "I'm sticking with it."

• [By Lisa Levin]

  Tyson Foods, Inc. (NYSE: TSN) reported weaker-than-expected results for its fiscal second quarter.

  Tyson posted quarterly earnings of $1.271 per share on sales of $9.773 billion. Analysts expected earnings of $1.32 per share on sales of $9.89 billion. Tyson expects FY18 earnings of $6.55 to $6.70 per share.

Top 10 Penny Stocks To Invest In Right Now: BioDelivery Sciences International Inc.(BDSI)

Advisors' Opinion:

• [By Lisa Levin]

  BioDelivery Sciences International, Inc. (NASDAQ: BDSI) shares were also up, gaining 19 percent to $2.3272 after the company announced board restructuring plan and $50m equity financing deal led by Broadfin to "significantly strengthen" financial position.

Top 10 Penny Stocks To Invest In Right Now: Smith Micro Software Inc.(SMSI)

Advisors' Opinion:

• [By Stephan Byrd]

  These are some of the news stories that may have impacted Accern’s scoring:

  Get Smith Micro Software alerts: Short Interest in Smith Micro Software (SMSI) Increases By 51.9% (americanbankingnews.com) Smith Micro Software’s (SMSI) CEO Bill Smith on Q1 2018 Results – Earnings Call Transcript (seekingalpha.com) Smith Micro Software (SMSI) Reports Q1 Loss of $0.10 (streetinsider.com) Smith Micro Reports First Quarter 2018 Financial Results (finance.yahoo.com) Smith Micro announces above market USD 7.0m private placement offering (financial-news.co.uk)

  Separately, ValuEngine upgraded shares of Smith Micro Software from a “sell” rating to a “hold” rating in a report on Friday, February 2nd.

Top 10 Penny Stocks To Invest In Right Now: NRG Energy Inc.(NRG)

Advisors' Opinion:

• [By Ethan Ryder]

  DTE Energy (NYSE: DTE) and NRG Energy (NYSE:NRG) are both utilities companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.